Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Unless you are trading this stock for short-term moves, it makes no sense at all to worry about every wiggle and waggle in the share price.
Today is an example of how this stock can bolt higher without any warning.
Yes, the fact that they are now an SEC fully-reporting company is good news for raising capital to move ahead with commercialization of the CTS 2.0 technology.
Without audited financials they would be stymied in the capital markets.
ALLM 2020 Annual report:
https://www.sec.gov/Archives/edgar/data/1549145/000149315221008113/form10-k.htm
No one is going to be able to obtain non-public information from either the company or the company's auditor, Marcum, LLC.
Sounds like someone is sending their attorney on a wild goose chase.
Every situation is different.
Without knowing all of the details it is hard to draw comparisons.
It will get done, when it gets done.
Fretting over the timeline serves no purpose other than to create frustration and stress.
You are suggesting that people refrain from buying a company because of volatility in the price of the shares, rather than the solid long-term fundamentals?
It certainly sounds like a very myopic view of investing, and anyone that listens to such a suggestion is also failing to focus on what is important.
<<"Until this stops I would recommend people quit buying this stock.">>
These clowns couldn't raise any capital at $3.50, so they are now trying at $2.50.
https://www.otcmarkets.com/filing/html?id=14814877&guid=oBApUF378EWht3h
Why is any of this relevant?
The Market Makers are simply playing their usual games, and there is nothing anyone can do about it.
Why do you keep beating a dead horse? It's a waste of time and energy.
The bid/ask spread is so wide, you can drive an 18-wheeler through it.
This is not unusual for a low-float stock with limited shares available for trading.
It's hard to believe that in a few more weeks, on April 5th, it will have been 4 years since we first wrote about Glucose Health.
https://seekingalpha.com/instablog/22758161-altitrade-partners/5570156-glucose-health-inc-gluc-addressing-growing-diabetes-epidemic-why-this-highly-speculative-low
https://www.zerohedge.com/commodities/bidens-green-energy-push-sparks-surge-global-cooking-oil-prices
"There's a confluence of factors mentioned above as the trend in rising food prices appears to be gaining momentum."
We agree that the future for corn-based ethanol producers like GEVO does not look good. More corn-based ethanol plants could also get shuttered if the trend in rising food prices continues unabated.
<<"Green darling GEVO posted 4th QTR results. The future does not look good. They closed their ethanol plant in Lucerne">>.
We agree.
However, reading through the posts on this board, it is obvious that few here have an appreciation, as well as an understanding, of what is actually involved in getting three years of financial statements reconstructed and audited.
Constant complaining, along with hurling insults at management, is not going solve anything.
We recently went through a similar situation with ALLM. They also had a number of years where they were not current with their financial statements, due to their filing a Form 15-12G and choosing to go dark.
https://www.otcmarkets.com/filing/html?id=13057821&guid=BMpaUnLBMuT6M3h
The auditors require every "i" dotted and every "t" crossed before they will sign off on the financials.
Generally speaking, it takes longer than expected. That's the bad news.
The good news is that once ALLM filed their Form 10-12G, and became a fully-reporting company again, the stock reacted very favorably.
https://www.otcmarkets.com/filing/html?id=14598553&guid=BMpaUnLBMuT6M3h
We expect a similar "relief rally" in CRXM once they file and get current on the pink sheets.
More than anything, else investors need to be patient.
We are always looking for micro-caps with a catalyst to change the investment dynamics of the company.
https://seekingalpha.com/instablog/22758161-altitrade-partners/5566784-finding-right-catalyst-in-micro-cap-stock-can-produce-huge-returns-are-three-of-favorites
Item 5.01 Changes in Control of Registrant.
The sale of the Series B Convertible Preferred Stock resulted in a change of control in our company. The 1,700,000 shares of Series B Convertible Preferred Stock issued to Nostrum vote on an as converted basis with the equivalence of 150,442,478 shares of Common Stock.
Concurrently with the sale of the Series B Convertible Preferred Stock, Nostrum acquired 220 shares of our Series A Convertible Preferred Stock from Sabby Master Healthcare Ltd. and agreed to purchase the remaining 570 shares of Series A Convertible Preferred Stock that are outstanding and held by Sabby. As a result of the issuance of the Series B Convertible Preferred Stock, each share of our Series A Convertible Preferred Stock became convertible into 88,496 shares of our Common Stock. The Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock restricts Nostrum from converting any Series A Preferred Stock if Nostrum would beneficially own a number of shares of Common Stock in excess of 9.99% of the shares of Common Stock then issued and outstanding. As a result of its ownership of the Series B Convertible Preferred Stock, Nostrum is currently limited in its entirety from converting any shares of Series A Convertible Preferred Stock. The Series A Convertible Preferred Stock has no voting rights on general corporate matters, provided that the Series A Convertible Preferred Stock contain customary protective provisions. We were not a party to, and did not receive any proceeds from, the sale of the Series A Convertible Preferred Stock between Nostrum and Sabby.
We currently have 14,489,399 shares of Common Stock outstanding. Consequently, Nostrum’s current investment in the Series B Convertible Preferred Stock represents control of 91.2 percent of the voting power of the Company.
Nostrum acquired the Series B Convertible Preferred Stock in exchange for $1.7 million, which was funded from working capital. We are not aware of any other transaction that could result in a subsequent change in control of the Company.
https://www.otcmarkets.com/filing/html?id=14182106&guid=BMpaUnLBMuT6M3h
6.1 SEC Filings. The Company has engaged Marcum, LLP (“Marcum”) to prepare the Company’s financial statements for the years ended December 31, 2017, 2018 and 2019 that are required to be filed with Securities and Exchange Commission (“SEC”) pursuant to the Exchange Act in order to cause the Company to become current with its reporting obligations. The expense incurred for such financial statement preparation, up to $120,000, will be paid by the Company from the proceeds of the sale of the Shares. It is understood that the Company is delinquent in its SEC reporting obligations and the Company and its officers and directors shall use their reasonable best efforts to assist Marcum so as to ensure that the Company becomes current with such obligations. Within four (4) Business Days after the Closing, the Company will file a current report on Form 8-K disclosing the change of control contemplated by this Agreement.
https://contracts.justia.com/companies/gene-biotherapeutics-inc-7110/contract/119376/
3.7 Financial Statements; Settlement of Claims.
(a) Complete copies of (i) the Company’s unaudited financial statements consisting of the balance sheet of the Company as at December 31 in each of the years 2018 and 2017 and the related statements of operations and cash flow for the years then ended (the “Annual Financial Statements”) and (ii) the Company’s unaudited financial statements consisting of the balance sheet of the Company as at May 31, 2019 and the related statement of income for the five (5) months then ended (the “Interim Financial Statements” and, together with the Annual Financial Statements, the “Financial Statements”). The Financial Statements are attached to Schedule 3.7(a). The balance sheet of the Company as of May 31, 2019 is referred to herein as the “Balance Sheet” and the date thereof as the “Balance Sheet Date”. The Financial Statements: (i) were prepared from the books and records of the Company; and (ii) fairly present the consolidated financial position of the Company and its Subsidiaries as of the respective dates thereof and the consolidated results of operations and cash flows of the Company and its Subsidiaries for the periods covered thereby.
(b) Schedule 3.7(b) sets forth a correct and complete list of all creditor claims against the Company.
(c) Schedule 3.7(c) sets forth a correct and complete list of all claims by employees and former employees of the Company for accrued and unpaid deferred salary.
https://contracts.justia.com/companies/gene-biotherapeutics-inc-7110/contract/119376/
3.6 SEC Filings. The Company currently is, and since August 14, 2017 has been, delinquent with its filings with the SEC. As used herein, the “Company SEC Documents” means all reports, schedules, forms, statements and other documents filed or furnished, as applicable, by the Company under the Securities Act and/or the Exchange Act prior to August 14, 2017. None of the Company SEC Documents, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein in light of the circumstances under which they were made not misleading.
https://contracts.justia.com/companies/gene-biotherapeutics-inc-7110/contract/119376/
Perhaps even more than that.
"Novel anti-anginal therapies are few and far between. There has been only one anti-anginal drug with a novel mechanism of action approved by the FDA in the past half-century (Gilead’s Ranexa), which was acquired one year following FDA approval for $1.4 billion."
https://www.nytimes.com/2009/03/13/business/13biotech.html
<<"The drug will be worth over $800 million on a buyout.">>
All of these corn-ethanol producers are going to get slammed with the huge increase in agricultural commodity prices that are coming.
Blue Biofuels, on the other hand, sits quietly in the background waiting to benefit from the carnage of a ravaged corn-ethanol industry that will be unable to find a way to make money, unless they can transition to producing cellulosic ethanol.
https://seekingalpha.com/article/4410721-soaring-commodity-prices-make-ethanol-unprofitable-blue-biofuels-offers-alternative
Gevo's struggles are actually good news for ALLM for two reasons:
1. If Gevo were to adopt Blue Biofuel's CTS 2.0 technology, thus reducing their costs to produce ethanol, it could change their poor financial performance. Gevo management certainly might find that to be attractive.
2. Closing the plant in Lucerne just gives Blue Biofuels another target for potential purchase with any new strategic partner(s).
Gevo's weakness and poor results help to open the door for ALLM to get their foot inside with their superior technology. Gevo is not the only ethanol producer struggling with the combined problems of high feedstock costs and a cumbersome, and financially burdensome, method of converting sugar to ethanol using enzymes and other expensive additives.
We would not be surprised to see some sort of a possible joint venture emerge down the road between GEVO and ALLM.
Things may be getting worse for GEVO, but it appears that they are certainly beginning to improve for ALLM, despite your protestations to the contrary.
It's actually pretty simple. When you have a large spread in a stock, there can be huge gaps in price when trades are executed.
We've recently seen a bid/ask spread as high as 10% plus in GLUC on a couple of occasions.
If the stock is bid at $5.00 and offered at $5.25, someone selling is going to get the bid price and someone buying will get filled at the ask price.
Trades going through within minutes of each other will cause the wild swings that you are trying to so hard to understand.
If there is any manipulation in this stock (which we doubt) it is likely due to Market Maker activities.
While you may have been trading stocks for 40 years, we doubt that you have ever traded in a OTC stock with such a low number of shares in the public float as GLUC has.
If you are a long-term investor, as you claim to be, why do you even worry about such mundane, picayune stuff?
Magmar, it has become very obvious that you are not just a casual observer of ALLM.
It seems that you may be part of the old regime at Carbolosic that has been terminated for reasons that we will not get into on this message board.
Suffice to say that you have an “ax to grind” and as a result your opinions are skewed and tainted by your apparent feelings of vindictiveness.
Those of us who believe in the future of this company will not give you the satisfaction of undermining our confidence in the future of ALLM.
Just take a look at GEVO shares.
https://www.stockscores.com/charts/charts/?ticker=gevo
Anything is possible in this crazy market environment.
Only for a brief moment.
Now back down to $3.47.
This stock can't seem to get out of its own way.
Still don't know why they think that they can do a capital raise at $3.50 with virtually no discount to the market price.
The shares will need to get to at least $5.00 to attract any meaningful buying interest.
Judging by the reaction of the stock price, nobody was impressed.
For the record, we have not sold a single share of ALLM stock during this recent run-up.
The title is "Why Corn Makes Terrific Biofuel" taken directly from GEVO's website (see the link below):
(Open Quote): "Gevo uses inedible field corn as feedstock to make isobutanol and there are numerous reasons why it works:
There’s plenty of corn around. Gevo’s Luverne, Minnesota, facility is situated amid thousands of acres of cornfields, since it’s a converted ethanol plant. That means reduced transportation cost (and emissions) to get the corn to the plant.
Corn growing is a science, and, while the weather and other conditions affect yield, it produces a huge biomass growth over the course of the three- to four-month growing season. That’s carbon getting captured from the atmosphere through photosynthesis.
When the corn gets to the plant, it is separated into its components, and the starch goes to the fermentation process to make biofuel, while the protein becomes animal feed.
Zone-tilling means the farmers leave the roots of last years crop and plow a very narrow row between. As the root ball of each stalk decays in the ground, it’s carbon becomes part of the soil.
High-protein animal feed helps livestock be healthier and also produce nutrient-rich manure that is then spread over the fields, preventing the farmer from needing to buy synthetic fertilizer and pay a crew to spread it." (Close Quote)
https://gevo.com/agriculture/corn-and-the-carbon-cycle/
The problem with using corn to produce ethanol is that corn prices, along with all commodities, are extremely volatile.
Higher corn prices make it almost impossible to produce ethanol from corn profitably.
And also about the biofuel industry, in general.
That would, by default, include other companies in the competitive landscape.
Yes, and much of that future progress is already factored into GEVO's stock price.
ALLM is just getting started; hence the low valuation and stock price.
GEVO's stock price was 50 cents in August of 2020. It currently stands at almost $12.00.
A 24-bagger !!! Very nice.
ALLM's stock price is at 50 cents now.
Comparing the upside of the two companies from here, we're inclined to favor ALLM.
<<"In short, they are ready for a huge expansion.">>